Insulet (PODD) Reworks Debt Terms, Is It Still Trading At A Discount?
Insulet (PODD) recently reworked its credit agreement, swapping US$475 million of term loans into new debt with lower interest margins and expanding its revolving credit facility to US$750 million, which remained fully undrawn.
Recent trading tells a different story than the balance sheet work. Insulet’s share price is down 17.6% over the past 90 days and 53.5% year to date, while the 1 year total shareholder return has declined 57.4%. This suggests momentum has been fading even as management works to trim financing costs.
Scan beyond Insulet and size up other healthcare stocks with resilient balance sheets and cash flow support using our curated list of solid balance sheet and fundamentals (25 results)
Insulet has reduced its financing costs while the share price has already reset significantly. The next issue is whether current levels still leave meaningful upside available to investors, or if the easier part of the rerating has already taken place.
Most Popular Narrative: 23% Undervalued
Insulet last closed at $131.69, while the most followed narrative anchors fair value at $171.91. The story on paper therefore looks more optimistic than the recent share price reset suggests.
A robust product and algorithm roadmap, including recent Omnipod 5 enhancements such as a 100 mg/dL glucose target and Libre 3 Plus integration, the Omnipod 6 pivotal data showing higher time in range and fewer boluses, and a fully closed loop type 2 system in pivotal trials for a planned 2028 launch, creates multiple future upgrade cycles that can support higher revenue and potentially higher net margins as users migrate to newer systems.
See why 23 investors see Insulet as 23% undervalued.
The narrative applies a 7.67% discount rate and arrives at a fair value of $171.91, which implies Insulet trades at a 23.4% discount to that central case today. That gap reflects a view that the recurring Omnipod pod model and product roadmap are not fully reflected in the current share price, even after factoring in recall and retention risks discussed in the same narrative.
Result: Fair Value of $171.91 (UNDERVALUED)
Still, the Insulet narrative depends on type 2 users continuing to use pods despite weaker early retention and on recall-related quality issues not eroding clinician trust.
Find out about the key risks to this Insulet narrative.
Next Steps
Sentiment around Insulet is mixed in the short term, so move quickly and stress test the story against your own expectations by reviewing the 4 key rewards
Looking for more Insulet investment ideas?
If Insulet has sharpened your focus on where your money works hardest, do not stop here. Use this moment to widen your opportunity set and pressure test your next move.
- Target mispriced quality and see if any stocks on your radar line up with the 31 high quality undervalued stocks.
- Prioritise staying power and stress test your holdings against a 31 resilient stocks with low risk scores that keeps downside firmly in view.
- Hunt for tomorrow's leaders early and compare your watchlist with a focused 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com